查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1918188

多发性骨髓瘤市场－2026-2031年预测

Multiple Myeloma Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 150 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

多发性骨髓瘤市场预计将从 2025 年的 262.31 亿美元成长到 2031 年的 376.7 亿美元，复合年增长率为 6.22%。

多发性骨髓瘤市场是血液肿瘤学领域一个充满活力且快速发展的细分市场，专注于骨髓浆细胞恶性肿瘤的治疗。该疾病以高復发率和抗药性为特征，因此需要持续开发平臺新型治疗方法，这使得该市场成为临床研究和医药投资的重要中心。

核心临床挑战与治疗模式

儘管多发性骨髓瘤仍是一种无法治癒的癌症，但其治疗效果已稳步提升，治疗策略的核心在于实现深度且持久的缓解、控制症状并维持患者的生活品质。治疗模式已发生巨大变化，从依赖传统化疗和糖皮质激素转变为多管齐下的综合治疗，包括免疫调节剂、蛋白酶体抑制剂、单株抗体，以及近年来兴起的先进细胞疗法和双特异性免疫疗法。治疗通常采用序贯给药的方式，根据患者的病情、疾病风险分层和既往治疗史选择合适的方案，体现了复杂且个人化的治疗理念。

主要市场成长驱动因素

市场扩张的根本驱动力是全球疾病发生率的上升，而这与人口老化密切相关。老龄化就是一个主要的风险因素，它导致目标患者数量不断增加，尤其是在人口老化的已开发国家。这种人口趋势持续催生了对有效治疗方法的潜在需求。

然而，最强劲的成长要素是治疗方法创新和新药认证的加速。监管环境瞬息万变，包括靶向B细胞成熟抗原（BCMA）的治疗方法在内的新型作用机制药物不断核准，例如双特异性T细胞衔接器和嵌合体抗原受体（CAR）T细胞疗法。这些核准持续拓展復发难治性疾病的治疗选择，并逐步纳入早期治疗方案。这显着延长了治疗路径，并提升了市场价值。

疾病认知度的提高和早期诊断的普及也促进了市场成长。患者权益组织和专业协会所进行的教育活动提高了基层医疗服务提供者和公众对疾病症状的识别能力，从而促进了早期转诊和诊断。早期疗育疾病进程可以提高有效治疗的几率，改善长期预后，使更多患者能够积极参与长期管理。

对生物医学研究的持续大规模投入正在推动这一市场的发展。对疾病生物学、肿瘤微环境交互作用以及抗药性机制的深入理解，正引领一系列标靶治疗和免疫疗法的研发。公营和私营製药公司的巨额资金支持着这项研究，从而营造了一个竞争激烈、创新氛围浓厚的环境。

市场机会与不断演变的前沿领域

未来成长的关键机会体现在以下几个方面：第一线治疗越来越注重早期治疗，包括新诊断病例和高风险隐匿性多发性骨髓瘤，旨在阻止疾病进展。基于基因组分析和微量残存疾病（MRD）监测的个人化治疗策略的开发，为优化治疗效果和调整治疗强度提供了重要机会。

此外，随着新兴经济体诊断和治疗基础设施的完善，市场有望进一步扩大，这主要得益于医疗资源的改善和应用范围的扩大。探索新型药物联合治疗和治疗顺序策略，以克服抗药性并提高疗效，仍然是临床研发的核心重点。

市场限制与临床挑战

市场本身就存在着许多挑战。抗药性的出现是限制现有疗法长期治疗方法的根本性生物学障碍，因此需要不断研发新型药物。此疾病的复杂性和异质性，以及众多的遗传亚型，使得开发普遍有效的治疗方法变得极具挑战性。

此外，新型强效治疗方法的毒性，包括细胞激素释放症候群、神经毒性和长期血球减少症，为治疗管理带来了重大挑战。这些毒性会影响患者的生活质量，需要专业的临床支持，并可能限制治疗方法在体弱老年患者中的应用。

区域情势和趋势

北美在全球多发性骨髓瘤市场占据主导地位，这得益于其高发病率、完善的临床试验基础设施（能够快速推出新型治疗方法）、有利的医保报销环境以及众多大型研究机构和製药公司的聚集。该地区通常是创新高成本治疗方法的首发市场和主要收入来源。

竞争格局与策略重点

竞争环境十分激烈，既有大型跨国製药公司，也有专业生技公司参与其中。策略活动着重于广泛的研发，以开发下一代治疗方法，包括新型CAR-T构建体、具有新标靶的双特异性抗体和抗体药物复合体。

各公司正大力投资大规模临床试验，以推进药物进入早期治疗阶段，并在治疗序列中占据主导地位。现有药物的生命週期管理也是一项关键策略，目前正在进行新型联合治疗的研究和皮下製剂的开发。大型製药企业与生技创新者之间的合作和授权协议也十分普遍，加速了药物的研发和商业化进程。

未来市场趋势

多发性骨髓瘤市场的未来发展方向是：采用日益精细化的免疫疗法，以功能性治癒为治疗目标，并制定更个人化的治疗方案。针对BCMA以外的新标靶的新型态治疗方法研发工作已经展开。将细胞疗法和双特异性抗体整合到第一线治疗方案中，将重新定义多发性骨髓瘤的治疗标准。

市场参与企业要想取得长期成功，需要在竞争激烈的市场环境中展现卓越的疗效和可控的安全性，成功应对高成本治疗的复杂报销流程，并製定应对抗药性的策略。作为肿瘤学领域的创新典范，多发性骨髓瘤市场以持续的科学进步为特征，旨在将曾经令人绝望的疾病转变为一种可控的慢性疾病，从而确保其持续发展和进步。

本报告的主要优势：

  • 深入分析：获得主要和新兴地区的深入市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、行业垂直领域和其他细分市场。
  • 竞争格局：了解全球主要参与者的策略倡议，并了解透过正确的策略实现市场渗透的潜力。
  • 市场驱动因素与未来趋势：探索市场驱动因素和关键趋势及其对未来市场发展的影响。
  • 可操作的建议：利用这些见解，在快速变化的环境中製定策略决策，发展新的商业机会和收入来源。
  • 受众广泛：适用于Start-Ups、研究机构、顾问公司、中小企业和大型企业，且经济实惠。

以下是一些公司如何使用这份报告的范例

产业与市场分析、机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法规结构及影响、新产品开发、竞争情报

报告范围：

  • 2022年至2024年的历史数据和2025年至2031年的预测数据
  • 成长机会、挑战、供应链前景、法规结构与趋势分析
  • 竞争定位、策略和市场占有率分析
  • 按业务板块和地区（包括国家）分類的收入和预测评估
  • 公司概况（策略、产品、财务资讯、关键发展等）

目录

第一章执行摘要

第二章 市场概览

  • 市场概览
  • 市场定义
  • 调查范围
  • 市场区隔

第三章 商业情境

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策与法规
  • 策略建议

第四章 技术展望

5. 多发性骨髓瘤市场（按类型划分）

  • 介绍
  • 隐性多发性骨髓瘤
  • 活动性多发性骨髓瘤

6. 多发性骨髓瘤市场（依治疗方法）

  • 介绍
  • 化疗
  • 标靶治疗
  • 免疫疗法
  • 干细胞移植
  • 皮质类固醇

7. 依诊断分类的多发性骨髓瘤市场

  • 介绍
  • 血液检查
  • 骨髓切片检查
  • 尿液检查

8. 多发性骨髓瘤市场（以最终用户划分）

  • 介绍
  • 医院和诊所
  • 居家医疗
  • 其他的

9. 多发性骨髓瘤市场（按地区划分）

  • 介绍
  • 北美洲
    • 按类型
    • 透过治疗方法
    • 透过诊断
    • 最终用户
    • 按国家/地区
      • 我们
      • 加拿大
      • 墨西哥
  • 南美洲
    • 按类型
    • 透过治疗方法
    • 透过诊断
    • 最终用户
    • 按国家/地区
      • 巴西
      • 阿根廷
      • 其他的
  • 欧洲
    • 按类型
    • 透过治疗方法
    • 透过诊断
    • 最终用户
    • 按国家/地区
      • 英国
      • 德国
      • 法国
      • 西班牙
      • 其他的
  • 中东和非洲
    • 按类型
    • 透过治疗方法
    • 透过诊断
    • 最终用户
    • 按国家/地区
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 其他的
  • 亚太地区
    • 按类型
    • 透过治疗方法
    • 透过诊断
    • 最终用户
    • 按国家/地区
      • 中国
      • 日本
      • 印度
      • 韩国
      • 台湾
      • 其他的

第十章 竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 合併、收购、协议和合作
  • 竞争对手仪錶板

第十一章 公司简介

  • Revlimid
  • Bristol-Myers Squibb
  • Abecma
  • Novartis
  • Pomalyst
  • Takeda Pharmaceuticals
  • Johnson & Johnson
  • Innate Pharma
  • Janssen

第十二章附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要收益
  • 调查方法
  • 简称
简介目录
Product Code: KSI061616015

Multiple Myeloma Market is projected to expand at a 6.22% CAGR, reaching USD 37.67 billion in 2031 from USD 26.231 billion in 2025.

The multiple myeloma market represents a dynamic and rapidly evolving segment within hematological oncology, focused on a malignancy of plasma cells in the bone marrow. Characterized by a high relapse rate and the development of treatment resistance, the disease necessitates a continuous pipeline of novel therapeutic approaches, making this market a hub for significant clinical research and pharmaceutical investment.

Core Clinical Challenge and Therapeutic Paradigm

Multiple myeloma remains an incurable but increasingly treatable cancer, with management strategies centered on achieving deep and durable remissions, controlling symptoms, and preserving quality of life. The therapeutic landscape has shifted dramatically from reliance on traditional chemotherapy and corticosteroids to a multifaceted arsenal including immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, and, most recently, advanced cellular and bispecific immunotherapies. Treatment is typically administered in sequences, with regimens selected based on patient fitness, disease risk stratification, and prior therapy, reflecting a complex and personalized approach to care.

Primary Market Growth Drivers

Market expansion is fundamentally driven by the rising global incidence of the disease, which is strongly correlated with an aging population. As the predominant risk factor, increasing age ensures a growing addressable patient population, particularly in developed economies with aging demographics. This demographic trend provides a sustained baseline demand for effective therapies.

The most powerful growth vector, however, is the accelerated pace of therapeutic innovation and new drug approvals. The regulatory landscape has been highly active, with approvals for novel mechanisms of action, including B-cell maturation antigen (BCMA)-targeted therapies such as bispecific T-cell engagers and chimeric antigen receptor (CAR) T-cell therapies. These approvals continually expand the treatment repertoire for relapsed/refractory disease and are progressively moving into earlier lines of therapy, significantly lengthening treatment pathways and driving market value.

Increased disease awareness and earlier diagnosis also contribute to market growth. Educational initiatives by patient advocacy groups and professional societies have improved recognition of symptoms among primary care providers and the public, leading to earlier specialist referral and diagnosis. Earlier intervention in the disease course expands the window for effective treatment and improves long-term outcomes, thereby integrating more patients into active, long-term management pathways.

Substantial and ongoing investment in biomedical research underpins the market's evolution. A deepening understanding of disease biology, tumor microenvironment interactions, and mechanisms of resistance is translating into a rich pipeline of targeted agents and immunotherapies. This research is supported by significant funding from both public institutions and private pharmaceutical companies, fostering a competitive and innovative environment.

Market Opportunities and Evolving Frontiers

Key opportunities for future growth lie in several areas. The frontier of treatment is increasingly focused on earlier lines of therapy, including newly diagnosed and even high-risk smoldering myeloma, aiming to prevent progression. The development of personalized treatment strategies, guided by genomic profiling and minimal residual disease (MRD) monitoring, represents a major opportunity to optimize outcomes and tailor therapy intensity.

Furthermore, the market is poised for expansion through improved access and adoption in emerging economies, where diagnosis and treatment infrastructure are developing. The exploration of novel drug combinations and sequencing strategies to overcome resistance and deepen responses remains a central focus of clinical development.

Market Restraints and Clinical Hurdles

The market faces significant inherent challenges. The development of treatment resistance remains a fundamental biological obstacle, limiting the long-term efficacy of all current therapies and necessitating a continuous pipeline of novel agents. The complexity and heterogeneity of the disease, with numerous genetic subtypes, complicate the development of universally effective treatments.

Furthermore, the toxicity profiles of newer, more potent therapies-including cytokine release syndrome, neurotoxicity, and prolonged cytopenias-present substantial management challenges. These toxicities can impact patient quality of life, require specialized clinical support, and limit the applicability of therapies in frail or elderly populations.

Geographic Landscape and Regional Dynamics

North America maintains a leadership position in the global multiple myeloma market. This is attributable to a high disease prevalence, a robust clinical trial infrastructure that facilitates rapid adoption of new therapies, favorable reimbursement landscapes, and the presence of leading research institutions and pharmaceutical companies. The region often serves as the initial launch market and primary revenue generator for innovative, high-cost therapies.

Competitive Landscape and Strategic Focus

The competitive environment is intense and features both large multinational pharmaceutical companies and specialized biotechnology firms. Strategic activities are centered on extensive research and development to advance next-generation therapies, including novel CAR-T constructs, bispecific antibodies with new targets, and antibody-drug conjugates.

Companies are heavily invested in large-scale clinical trials to move their agents into earlier treatment lines and secure dominant positions in therapeutic sequences. Lifecycle management for established drugs, through new combination studies or subcutaneous formulations, is also a key strategy. Collaboration and licensing agreements between large pharma and biotech innovators are common, accelerating development and commercialization.

Future Market Trajectory

The future trajectory of the multiple myeloma market is oriented toward increasingly sophisticated immunotherapy, functional cure as a treatment goal, and greater personalization. The development of therapies with novel targets beyond BCMA is already underway. The integration of cellular therapies and bispecific antibodies into first-line treatment paradigms will redefine standards of care.

Long-term success for market participants will depend on demonstrating superior efficacy and manageable safety in competitive landscapes, navigating complex reimbursement pathways for high-cost therapies, and developing strategies to address treatment resistance. As a model for innovation in oncology, the multiple myeloma market is characterized by relentless scientific advancement aimed at transforming a once devastating diagnosis into a chronic, manageable condition, ensuring its continued expansion and evolution.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2022 to 2024 & forecast data from 2025 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Multiple Myeloma Market Segmentation

  • By Type
  • Smouldering Multiple Myeloma
  • Active Multiple Myeloma
  • By Treatment
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Stem Cell Transplantation
  • Corticosteroids
  • By Diagnosis
  • Blood Tests
  • Bone Marrow Biopsy
  • Urine Tests
  • By End-User
  • Hospitals & Clinics
  • Homecare
  • Others
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Taiwan
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. MULTIPLE MYELOMA MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Smouldering Multiple Myeloma
  • 5.3. Active Multiple Myeloma

6. MULTIPLE MYELOMA MARKET BY TREATMENT

  • 6.1. Introduction
  • 6.2. Chemotherapy
  • 6.3. Targeted Therapy
  • 6.4. Immunotherapy
  • 6.5. Stem Cell Transplantation
  • 6.6. Corticosteroids

7. MULTIPLE MYELOMA MARKET BY DIAGNOSIS

  • 7.1. Introduction
  • 7.2. Blood Tests
  • 7.3. Bone Marrow Biopsy
  • 7.4. Urine Tests

8. MULTIPLE MYELOMA MARKET BY END-USER

  • 8.1. Introduction
  • 8.2. Hospitals & Clinics
  • 8.3. Homecare
  • 8.4. Others

9. MULTIPLE MYELOMA MARKET BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. By Type
    • 9.2.2. By Treatment
    • 9.2.3. By Diagnosis
    • 9.2.4. By End-User
    • 9.2.5. By Country
      • 9.2.5.1. USA
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. South America
    • 9.3.1. By Type
    • 9.3.2. By Treatment
    • 9.3.3. By Diagnosis
    • 9.3.4. By End-User
    • 9.3.5. By Country
      • 9.3.5.1. Brazil
      • 9.3.5.2. Argentina
      • 9.3.5.3. Others
  • 9.4. Europe
    • 9.4.1. By Type
    • 9.4.2. By Treatment
    • 9.4.3. By Diagnosis
    • 9.4.4. By End-User
    • 9.4.5. By Country
      • 9.4.5.1. United Kingdom
      • 9.4.5.2. Germany
      • 9.4.5.3. France
      • 9.4.5.4. Spain
      • 9.4.5.5. Others
  • 9.5. Middle East and Africa
    • 9.5.1. By Type
    • 9.5.2. By Treatment
    • 9.5.3. By Diagnosis
    • 9.5.4. By End-User
    • 9.5.5. By Country
      • 9.5.5.1. Saudi Arabia
      • 9.5.5.2. UAE
      • 9.5.5.3. Others
  • 9.6. Asia Pacific
    • 9.6.1. By Type
    • 9.6.2. By Treatment
    • 9.6.3. By Diagnosis
    • 9.6.4. By End-User
    • 9.6.5. By Country
      • 9.6.5.1. China
      • 9.6.5.2. Japan
      • 9.6.5.3. India
      • 9.6.5.4. South Korea
      • 9.6.5.5. Taiwan
      • 9.6.5.6. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Competitive Dashboard

11. COMPANY PROFILES

  • 11.1. Revlimid
  • 11.2. Bristol-Myers Squibb
  • 11.3. Abecma
  • 11.4. Novartis
  • 11.5. Pomalyst
  • 11.6. Takeda Pharmaceuticals
  • 11.7. Johnson & Johnson
  • 11.8. Innate Pharma
  • 11.9. Janssen

12. APPENDIX

  • 12.1. Currency
  • 12.2. Assumptions
  • 12.3. Base and Forecast Years Timeline
  • 12.4. Key Benefits for the Stakeholders
  • 12.5. Research Methodology
  • 12.6. Abbreviations